📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sadhana Nitrochem Allots 263.5 Crore Equity Shares via Rights Issue at ₹1 Each
Sadhana Nitrochem Limited has successfully completed the allotment of 263,52,83,328 equity shares following its Rights Issue. The shares were issued at a price of ₹1 per equity share, significantly expanding the company's equity base. As a result, the paid-up equity share capital has increased from ₹32.94 crore to ₹296.47 crore. While 5,128 shares are kept in abeyance pending clearances, the new shares will rank pari-passu with existing equity.
Key Highlights
Allotment of 263,52,83,328 fully paid-up equity shares at an issue price of ₹1 per share
Paid-up equity share capital increased from ₹32,94,11,057 to ₹2,96,46,94,385
5,128 Rights Equity Shares kept in abeyance pending regulatory or other clearances
New shares rank pari-passu in all respects with existing fully paid-up equity shares
💼 Action for Investors
Investors should be aware of the significant equity dilution as the share capital has increased nearly nine-fold. Monitor the company's utilization of these funds and the subsequent impact on Earnings Per Share (EPS).
Sadhana Nitrochem Sets February 19, 2026, as Record Date for Rights Issue
Sadhana Nitrochem Limited has officially designated February 19, 2026, as the record date for its upcoming Rights Issue. This date is crucial as it determines which shareholders are eligible to receive Rights Entitlements (REs) in their demat accounts. The company is proceeding with this capital raising activity in compliance with SEBI Listing and Disclosure requirements. Investors must hold the shares on or before this date to participate in the offering.
Key Highlights
The official record date for the Rights Issue is fixed for February 19, 2026.
The purpose is to identify shareholders eligible for Rights Entitlements under the proposed issue.
The announcement follows compliance with Regulation 42 of SEBI LODR and Regulation 68 of SEBI ICDR.
The ISIN for the Rights Entitlement is identified as INE888C20024.
💼 Action for Investors
Existing shareholders should check the rights price and ratio once announced to decide on exercising their rights. Those wishing to participate must ensure they hold the shares by the record date to receive entitlements.
Sadhana Nitrochem Approves ₹263.53 Crore Rights Issue with 8:1 Ratio
Sadhana Nitrochem Limited has finalized the terms for a significant rights issue totaling ₹263.53 crore. The company will issue 263.53 crore new equity shares at a price of Re. 1 per share, which is at par with the face value. Existing shareholders are entitled to 8 new shares for every 1 share held as of the record date. The record date for this corporate action is set for February 19, 2026.
Key Highlights
Total rights issue size fixed at ₹26,352.92 lakhs (approximately ₹263.53 crore)
Rights entitlement ratio set at 8 fully paid-up equity shares for every 1 share held
Issue price determined at Re. 1 per share, representing zero premium over face value
Record date for eligibility established as February 19, 2026
Total number of fresh rights shares to be issued is 263,52,92,056
💼 Action for Investors
Investors should be aware of the massive equity dilution resulting from the 8:1 ratio and decide whether to subscribe to maintain their ownership percentage. Monitor the stock price closely as it will likely adjust significantly on the ex-rights date.
Sadhana Nitrochem Q3 Results: Revenue Drops 81% YoY to ₹5.66 Cr; Posts ₹25.4 Cr Net Loss
Sadhana Nitrochem reported a dismal set of numbers for Q3 FY26, with revenue from operations crashing 81% YoY to ₹5.66 crore. The company swung to a net loss of ₹25.40 crore from a profit of ₹0.64 crore in the previous year's corresponding quarter. Management highlighted technical constraints, liquidity challenges, and US tariff-related trade uncertainties as the primary drivers for this downturn. For the nine-month period, the company has accumulated a net loss of ₹53.48 crore, significantly impacting its financial health.
Key Highlights
Quarterly revenue from operations plummeted to ₹566.26 lakhs from ₹2,975 lakhs YoY.
Net loss for Q3 FY26 widened to ₹2,540 lakhs compared to a profit of ₹64 lakhs in Q3 FY25.
Finance costs rose to ₹688 lakhs from ₹464 lakhs YoY, reflecting increased debt servicing pressure.
Total comprehensive loss for the nine-month period ended Dec 2025 stood at ₹5,361 lakhs.
Management cited US tariff uncertainties and technical production constraints as primary reasons for the decline.
💼 Action for Investors
The sharp decline in revenue and mounting losses suggest significant operational and external headwinds. Investors should remain cautious and monitor the promised Q4 recovery closely before making new commitments.
Sadhana Nitrochem Reports Q3 Net Loss of ₹25.4 Cr; Revenue Drops 81% YoY
Sadhana Nitrochem Limited reported a standalone net loss of ₹25.40 crore for the quarter ended December 31, 2025, a sharp decline from a profit of ₹0.64 crore in the same period last year. Revenue from operations fell significantly by 81% YoY to ₹5.66 crore, although it showed a sequential recovery from the previous quarter's low of ₹0.26 crore. The company cited technical production constraints, liquidity challenges, and global trade uncertainties in US and European markets as primary reasons for the poor performance. Management expects an operational recovery in Q4 FY26 as these issues have reportedly been addressed.
Key Highlights
Standalone revenue from operations plummeted 81% YoY to ₹5.66 crore from ₹29.75 crore.
Reported a net loss of ₹25.40 crore in Q3 FY26 against a profit of ₹0.64 crore in Q3 FY25.
9-month standalone net loss reached ₹53.48 crore compared to a profit of ₹1.23 crore in the prior year period.
Finance costs increased to ₹6.88 crore from ₹4.64 crore YoY, reflecting higher interest burden.
Management attributed losses to technical constraints and US tariff-related uncertainties affecting export schedules.
💼 Action for Investors
Investors should exercise caution as the company has transitioned to significant losses and a severely reduced revenue base. The stock remains a 'Watch' to see if the management's guidance of a Q4 recovery and resolution of technical/liquidity issues actually translates into improved financials.